A detailed history of Wetherby Asset Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Wetherby Asset Management Inc holds 45,030 shares of ABBV stock, worth $8.11 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares
45,030
Previous 45,439 0.9%
Holding current value
$8.11 Million
Previous $7.79 Million 14.1%
% of portfolio
0.42%
Previous 0.37%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $67,010 - $81,525
-409 Reduced 0.9%
45,030 $8.89 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $46,282 - $54,047
-299 Reduced 0.65%
45,439 $7.79 Million
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $70,160 - $79,941
439 Added 0.97%
45,738 $8.33 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $312,902 - $352,401
-2,274 Reduced 4.78%
45,299 $7.02 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $277,199 - $320,898
-2,075 Reduced 4.18%
47,573 $7.09 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $535,472 - $666,360
-4,041 Reduced 7.53%
49,648 $6.69 Million
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $561,665 - $646,841
-3,884 Reduced 6.75%
53,689 $8.56 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $101,519 - $121,748
734 Added 1.29%
57,573 $9.31 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $205,341 - $235,512
1,530 Added 2.77%
56,839 $7.63 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $155,372 - $197,529
1,129 Added 2.08%
55,309 $8.47 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $91,594 - $113,642
694 Added 1.3%
54,180 $8.78 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $131,816 - $166,786
1,227 Added 2.35%
53,486 $7.24 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $5,320 - $6,039
-50 Reduced 0.1%
52,259 $5.64 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $261,657 - $291,501
2,487 Added 4.99%
52,309 $5.89 Million
Q1 2021

May 14, 2021

SELL
$102.3 - $112.62 $251,351 - $276,707
-2,457 Reduced 4.7%
49,822 $5.39 Million
Q4 2020

Feb 11, 2021

BUY
$80.49 - $108.67 $280,266 - $378,388
3,482 Added 7.14%
52,279 $5.6 Million
Q3 2020

Dec 16, 2020

SELL
$85.91 - $100.83 $253,176 - $297,146
-2,947 Reduced 5.7%
48,797 $4.27 Million
Q3 2020

Nov 13, 2020

BUY
$85.91 - $100.83 $261,853 - $307,329
3,048 Added 6.26%
51,744 $4.53 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $1.22 Million - $1.63 Million
16,612 Added 51.78%
48,696 $4.78 Million
Q1 2020

May 06, 2020

BUY
$64.5 - $97.79 $123,840 - $187,756
1,920 Added 6.37%
32,084 $2.44 Million
Q4 2019

Jan 28, 2020

BUY
$72.13 - $90.25 $3,606 - $4,512
50 Added 0.17%
30,164 $2.67 Million
Q3 2019

Oct 31, 2019

SELL
$62.98 - $75.72 $18,201 - $21,883
-289 Reduced 0.95%
30,114 $2.28 Million
Q2 2019

Jul 25, 2019

BUY
$65.7 - $83.98 $69,839 - $89,270
1,063 Added 3.62%
30,403 $2.21 Million
Q1 2019

May 09, 2019

SELL
$77.14 - $90.79 $75,751 - $89,155
-982 Reduced 3.24%
29,340 $2.36 Million
Q4 2018

Jan 30, 2019

SELL
$77.85 - $96.01 $49,045 - $60,486
-630 Reduced 2.04%
30,322 $2.8 Million
Q3 2018

Nov 07, 2018

SELL
$88.91 - $98.84 $6,134 - $6,819
-69 Reduced 0.22%
30,952 $2.93 Million
Q2 2018

Jul 24, 2018

BUY
$89.78 - $106.23 $74,158 - $87,745
826 Added 2.74%
31,021 $2.87 Million
Q1 2018

May 04, 2018

BUY
$92.01 - $123.21 $7,912 - $10,596
86 Added 0.29%
30,195 $2.86 Million
Q4 2017

Feb 09, 2018

BUY
$89.56 - $98.21 $137,474 - $150,752
1,535 Added 5.37%
30,109 $2.91 Million
Q3 2017

Nov 13, 2017

BUY
$69.85 - $89.22 $2 Million - $2.55 Million
28,574
28,574 $2.54 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Wetherby Asset Management Inc Portfolio

Follow Wetherby Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wetherby Asset Management Inc with notifications on news.